Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283494 | 0.96 | DRD2 (0.45) | MAPTACSS2BCHEL3MBTL1HRH3 | |
| SCHEMBL1283519 | 0.90 | DRD2 (0.48) | MAPTACSS2BCHEMMP13L3MBTL1 | |
| SCHEMBL1283234 | 0.90 | DRD2 (0.48) | MAPTACSS2BCHEMMP13L3MBTL1 | |
| SCHEMBL1283448 | 0.88 | DRD2 (0.48) | BCHE | |
| SCHEMBL13314414 | 0.88 | KCNH2 (0.48) | MAPTACSS2BCHETSHRMMP13 | |
| SCHEMBL1283374 | 0.84 | DRD2 (0.50) | MAPTBCHETSHR | |
| SCHEMBL1283642 | 0.83 | DRD2 (0.43) | MAPTACSS2BCHEL3MBTL1HRH3 | |
| SCHEMBL1282611 | 0.82 | DRD2 (0.48) | MAPTACSS2BCHETSHRSMN1; SMN2 | |
| SCHEMBL1282958 | 0.81 | DRD2 (0.43) | MAPTACSS2BCHEL3MBTL1HRH3 | |
| SCHEMBL1283051 | 0.81 | MAOB (0.45) | BCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | MAPT 430/4885ACSS2 2898/4885BCHE 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.